SCHEMBL5200724

SCHEMBL5200724

CN1CCN(c2cccc3c2CCN(S(=O)(=O)c2ccccc2)C3)CC1

nearest known ligand 0.81

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 11/20 0.81
DRD3 P35462 8/20 0.81
DRD2 P14416 7/20 0.67
POLB P06746 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
LMNA P02545 1/20 0.54
MCOLN3 Q8TDD5 1/20 0.54
APOBEC3A P31941 1/20 0.52
APOBEC3G Q9HC16 1/20 0.52
HTR1A P08908 1/20 0.52
HTR2A P28223 1/20 0.52
GAA P10253 1/20 0.51
GFER P55789 1/20 0.51
HRH3 Q9Y5N1 1/20 0.51
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
AKR1C3 P42330 3/20 0.49
AKR1C1 Q04828 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6179536 0.87 HTR6 (0.62) HTR6DRD3DRD2MEN1KMT2A
SCHEMBL5204332 0.86 HTR6 (0.82) HTR6DRD3DRD2MEN1KMT2A
SCHEMBL27641069 0.83 HTR6 (0.57) HTR6DRD3DRD2MEN1KMT2A
SCHEMBL5204205 0.83 HTR6 (0.57) HTR6DRD3DRD2MEN1KMT2A
SCHEMBL5691960 0.80 HTR6 (0.65) HTR6DRD3DRD2MEN1KMT2A
Trifluoroacetic Acid SCHEMBL5205906 0.79 HTR6 (0.69) HTR6DRD3DRD2MEN1KMT2A
Tert-Butyl Formate SCHEMBL27641071 0.79 HTR6 (0.66) HTR6DRD3DRD2MEN1KMT2A
SCHEMBL5201623 0.77 HTR6 (0.64) HTR6DRD3DRD2MEN1KMT2A
SCHEMBL14626403 0.77 HTR6 (0.82) HTR6DRD3DRD2MEN1KMT2A
SCHEMBL21744255 0.76 MAOA (0.53) HTR6DRD3DRD2HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1601358-B1 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS HOFFMANN LA ROCHE (CH) 2007-12-19 EP claimed
US-7196088-B2 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC (US) 2007-03-27 US claimed
EP-1601358-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-07 EP claimed
US-20040180874-A1 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC 2004-09-16 US claimed
WO-2004078176-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-16 WO claimed
CN-100395237-C 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-HT6 modulators ROCHE PALO ALTO LLC (CH) 2008-06-18 CN disclosed
EP-1601358-B1 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
EP-1601358-B1 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
US-7196088-B2 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC (US) 2007-03-27 US disclosed
US-7196088-B2 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC (US) 2007-03-27 US disclosed
CN-1756550-A 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-HT6 modulators ROCHE PALO ALTO LLC (CH) 2006-04-05 CN disclosed
EP-1601358-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-07 EP disclosed
US-20040180874-A1 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC 2004-09-16 US disclosed
WO-2004078176-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180874-A1 Substituted tetrahydroisoquinolines and uses thereof CYP3A5, CYP4X1, UGT1A1 HTR6 1252/4885DRD3 291/4885DRD2 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.